Melanoma subtype influences immune-related adverse events in ICI therapy

Source: Healio, March 2023

Cutaneous immune-related adverse events are highly dependent on melanoma subtype among immune checkpoint inhibitor therapy recipients, according to a study.

According to Nga Nguyen, MD, MPH, of the department of dermatology at Massachusetts General Hospital in Boston, and colleagues, evidence has shown that the occurrence of cutaneous immune-related adverse events (cirAEs) may be related to improved survival among recipients of immune checkpoint inhibitor (ICI) therapy. This is especially true of those ICI therapy recipients with melanoma, the researchers wrote.

“However, benefits of ICI therapy have not been consistent across all melanoma subtypes,” Nguyen and colleagues continued, “with worse response in patients with acral, mucosal and uveal disease.”
READ THE ORIGINAL FULL ARTICLE